168 related articles for article (PubMed ID: 27296491)
1. Comparison of Short-Wavelength Reduced-Illuminance and Conventional Autofluorescence Imaging in Stargardt Macular Dystrophy.
Strauss RW; Muñoz B; Jha A; Ho A; Cideciyan AV; Kasilian ML; Wolfson Y; Sadda S; West S; Scholl HPN; Michaelides M
Am J Ophthalmol; 2016 Aug; 168():269-278. PubMed ID: 27296491
[TBL] [Abstract][Full Text] [Related]
2. COMPARISON OF MANUAL AND SEMIAUTOMATED FUNDUS AUTOFLUORESCENCE ANALYSIS OF MACULAR ATROPHY IN STARGARDT DISEASE PHENOTYPE.
Kuehlewein L; Hariri AH; Ho A; Dustin L; Wolfson Y; Strauss RW; Scholl HP; Sadda SR
Retina; 2016 Jun; 36(6):1216-21. PubMed ID: 26583307
[TBL] [Abstract][Full Text] [Related]
3. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
[TBL] [Abstract][Full Text] [Related]
4. ULTRAWIDEFIELD AUTOFLUORESENCE IN ABCA4 STARGARDT DISEASE.
Klufas MA; Tsui I; Sadda SR; Hosseini H; Schwartz SD
Retina; 2018 Feb; 38(2):403-415. PubMed ID: 28248825
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.
Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Mohand-Said S; Cideciyan AV; Birch D; Hariri AH; Nittala MG; Sadda S; Scholl HPN;
JAMA Ophthalmol; 2017 Jul; 135(7):687-695. PubMed ID: 28542697
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression.
Dysli C; Wolf S; Hatz K; Zinkernagel MS
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):832-41. PubMed ID: 26934141
[TBL] [Abstract][Full Text] [Related]
7. Insights into autofluorescence patterns in Stargardt macular dystrophy using ultra-wide-field imaging.
Kumar V
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1917-1922. PubMed ID: 28689222
[TBL] [Abstract][Full Text] [Related]
8. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
[TBL] [Abstract][Full Text] [Related]
9. [Fundus autofluorescence imaging in patients with Stargardt dystrophy and fundus flavimaculatus].
Dolar-Szczasny J; Mackiewicz J; Biziorek B; Zagórski Z
Klin Oczna; 2007; 109(4-6):176-8. PubMed ID: 17725280
[TBL] [Abstract][Full Text] [Related]
10. Quantitative fundus autofluorescence in recessive Stargardt disease.
Burke TR; Duncker T; Woods RL; Greenberg JP; Zernant J; Tsang SH; Smith RT; Allikmets R; Sparrow JR; Delori FC
Invest Ophthalmol Vis Sci; 2014 May; 55(5):2841-52. PubMed ID: 24677105
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the Rate of Ellipsoid Zone Loss in Stargardt Disease.
Cai CX; Light JG; Handa JT
Am J Ophthalmol; 2018 Feb; 186():1-9. PubMed ID: 29126757
[TBL] [Abstract][Full Text] [Related]
12. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479
[TBL] [Abstract][Full Text] [Related]
13. Fundus autofluorescence in Stargardt macular dystrophy-fundus flavimaculatus.
Lois N; Halfyard AS; Bird AC; Holder GE; Fitzke FW
Am J Ophthalmol; 2004 Jul; 138(1):55-63. PubMed ID: 15234282
[TBL] [Abstract][Full Text] [Related]
14. Near-infrared autofluorescence: its relationship to short-wavelength autofluorescence and optical coherence tomography in recessive stargardt disease.
Greenstein VC; Schuman AD; Lee W; Duncker T; Zernant J; Allikmets R; Hood DC; Sparrow JR
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3226-34. PubMed ID: 26024107
[TBL] [Abstract][Full Text] [Related]
15. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
Schönbach EM; Wolfson Y; Strauss RW; Ibrahim MA; Kong X; Muñoz B; Birch DG; Cideciyan AV; Hahn GA; Nittala M; Sunness JS; Sadda SR; West SK; Scholl HPN;
JAMA Ophthalmol; 2017 Jul; 135(7):696-703. PubMed ID: 28542693
[TBL] [Abstract][Full Text] [Related]
16. Correlations among near-infrared and short-wavelength autofluorescence and spectral-domain optical coherence tomography in recessive Stargardt disease.
Duncker T; Marsiglia M; Lee W; Zernant J; Tsang SH; Allikmets R; Greenstein VC; Sparrow JR
Invest Ophthalmol Vis Sci; 2014 Oct; 55(12):8134-43. PubMed ID: 25342616
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic heterogeneity and lesion size measurements in Stargardt macular dystrophy.
Shah SN; Koozekanani DD; Kim JE
Ophthalmic Surg Lasers Imaging; 2009; 40(5):506-12. PubMed ID: 19772279
[TBL] [Abstract][Full Text] [Related]
18. RETINAL FLECKS IN STARGARDT DISEASE REVEAL CHARACTERISTIC FLUORESCENCE LIFETIME TRANSITION OVER TIME.
Solberg Y; Dysli C; Escher P; Berger L; Wolf S; Zinkernagel MS
Retina; 2019 May; 39(5):879-888. PubMed ID: 30985551
[TBL] [Abstract][Full Text] [Related]
19. Morpho-functional correlation of fundus autofluorescence in Stargardt disease.
Parodi MB; Iacono P; Triolo G; La Spina C; Zucchiatti I; Cicinelli MV; Borrelli E; Manitto MP; Martina E; Bandello F
Br J Ophthalmol; 2015 Oct; 99(10):1354-9. PubMed ID: 25837607
[TBL] [Abstract][Full Text] [Related]
20. Automated Segmentation of Autofluorescence Lesions in Stargardt Disease.
Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera KT
Ophthalmol Retina; 2022 Nov; 6(11):1098-1104. PubMed ID: 35644472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
